News

AstraZeneca’s triple combination therapy Breztri Aerosphere, formerly known as PT010, has been approved in Japan for the treatment of symptoms of chronic obstructive pulmonary disease (COPD). This makes Japan the first country to grant regulatory approval for Breztri Aerosphere. Breztri Aerosphere, which is composed of budesonide, glycopyrronium…

Theravance Biopharma and Mylan have agreed to extend the development and commercialization of Yupelri (inhalation solution of revefenacin) — the first and only once-daily nebulized bronchodilator approved for chronic obstructive pulmonary disease (COPD) — to China and neighboring territories. The agreement could make Yupelri available…

New research suggests that monitoring inhaler usage electronically can reduce the number of hospital stays needed by people with chronic obstructive pulmonary disease (COPD). The study, titled “Electronic inhaler monitoring and healthcare utilization in chronic obstructive pulmonary disease,” was published in the Journal of Telemedicine and…

Note: This is the second article in a three-part series written in collaboration with respiratory therapist Mark W. Mangus Sr., RRT, RPFT, FAARC, and oxygen expert Ryan Diesem. The first part can be found here. When it comes to home improvement, people typically want three things from a contractor:…

Boehringer Ingelheim, the University Hospital Foundation, and the Government of Alberta, Canada, have formed a partnership aimed at implementing effective solutions to improve the lives of people with respiratory diseases, particularly chronic obstructive pulmonary disease (COPD). The Alberta Boehringer Ingelheim Collaboration (ABIC) was recently announced at the…

The use of inhaled steroids reduces the risk of developing lung cancer in people with chronic obstructive pulmonary disease (COPD), a study suggests. The study, titled “Inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease (COPD): a population-based cohort study,” was published…

Add-on treatment with asthma medication Fasenra (benralizumab) failed to reduce annual exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), according to final results of two Phase 3 trials. Findings were reported in the study, “Benralizumab for the Prevention of COPD Exacerbations,”…

Piedmont Atlanta announced that it is the first hospital in the state of Georgia to offer treatment for emphysema with the Zephyr Valve System, a minimally invasive therapy for better lung function and exercise tolerance without the need for surgery. Patients with emphysema, a severe form of chronic…

A post-hoc analysis showed that nebulized ensifentrine (RPL544) is highly effective for relieving respiratory symptoms in chronic obstructive pulmonary disease (COPD) patients with either reversible or non-reversible airway obstruction, although the effect is greater for those with reversible disease, according to Verona Pharma, ensifentrine’s developer. Over a treatment…

Verona Pharma started a Phase 2b dose-ranging study testing the safety and efficacy of nebulized ensifentrine (RPL554) as an add-on to a standard long-acting bronchodilator in people with moderate to severe chronic obstructive pulmonary disease (COPD), the company announced. The inhaled dual inhibitor ensifentrine targets the enzymes phosphodiesterase…